scholarly journals The JCR:LA-cp rat: a novel rodent model of cystic medial necrosis

2017 ◽  
Vol 312 (3) ◽  
pp. H541-H545 ◽  
Author(s):  
Yuh Fen Pung ◽  
William M. Chilian ◽  
Martin R. Bennett ◽  
Nichola Figg ◽  
Mohd Hamzah Kamarulzaman

Although there are multiple rodent models of the metabolic syndrome, very few develop vascular complications. In contrast, the JCR:LA-cp rat develops both metabolic syndrome and early atherosclerosis in predisposed areas. However, the pathology of the normal vessel wall has not been described. We examined JCR:LA control (+/+) or cp/cp rats fed normal chow diet for 6 or 18 mo. JCR:LA-cp rats developed multiple features of advanced cystic medial necrosis including “cysts,” increased collagen formation and proteoglycan deposition around cysts, apoptosis of vascular smooth muscle cells, and spotty medial calcification. These appearances began within 6 mo and were extensive by 18 mo. JCR:LA-cp rats had reduced medial cellularity, increased medial thickness, and vessel hypoxia that was most marked in the adventitia. In conclusion, the normal chow-fed JCR:LA-cp rat represents a novel rodent model of cystic medial necrosis, associated with multiple metabolic abnormalities, vascular smooth muscle cell apoptosis, and vessel hypoxia. NEW & NOTEWORTHY Triggers for cystic medial necrosis (CMN) have been difficult to study due to lack of animal models to recapitulate the pathologies seen in humans. Our study is the first description of CMN in the rat. Thus the JCR:LA-cp rat represents a useful model to investigate the underlying molecular changes leading to the development of CMN.

Hypertension ◽  
2016 ◽  
Vol 68 (suppl_1) ◽  
Author(s):  
Jessica Fry ◽  
Leona Al Sayah ◽  
Robert Weisbrod ◽  
Isabelle Van Roy ◽  
Xiang Weng ◽  
...  

Arterial stiffness (AS), a major cardiovascular risk factor, develops within two months in mice fed a high fat, high sucrose diet (HFHS), serving as a model of human metabolic syndrome, and is associated with functional impairment of vascular smooth muscle (VSM) cells. Sirtuin1 (SirT1) is a NAD + -dependent deacetylase induced in response to cellular stresses. Our goal was to study the effects of VSM SirT1 on AS in the context of diet-induced metabolic syndrome. VSM specific genetic SirT1 over-expression (SMTG) prevented AS induced by HFHS, measured in vivo by pulse wave velocity (PWV) over 8 months. Resveratrol or S17834, two polyphenolic compounds known to activate SirT1, prevented HFHS-induced AS and were mimicked by global SirT1 over-expression (SirBACO), without evident metabolic improvements (HFHS-induced weight gains or response to a glucose tolerance test remained unchanged). Additionally, HFHS-induced PWV increases were reversed by one-week treatment with a specific, small molecule SirT1 activator (SRT1720). Overnight fasting acutely decreased PWV in mice fed HFHS for 8 months, but not in mice lacking SirT1 in VSM (SMKO). These beneficial effects of pharmacological, genetic or fasting-induced SirT1 activation against AS, were associated with a decrease in NFκB activation and VCAM-1 and p47phox protein expressions, in aorta and VSM cells. In conclusion, VSM SirT1 activation decreases AS in the setting of obesity by stimulating anti-inflammatory and anti-oxidant pathways in the aortic wall. SirT1 activators may represent a novel therapeutic approach to prevent AS and associated CV complications in overweight/obese individuals with metabolic syndrome.


Sign in / Sign up

Export Citation Format

Share Document